ImmunityBio Inc. (IBRX)
| Bid | 3.06 |
| Market Cap | 2.67B |
| Revenue (ttm) | 17.16M |
| Net Income (ttm) | -481.38M |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | -5.04 |
| Forward PE | -7.33 |
| Analyst | Buy |
| Ask | 3.07 |
| Volume | 8,244,153 |
| Avg. Volume (20D) | 6,117,848 |
| Open | 3.41 |
| Previous Close | 3.36 |
| Day's Range | 3.02 - 3.47 |
| 52-Week Range | 2.28 - 10.53 |
| Beta | -0.18 |
About IBRX
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...
Analyst Forecast
According to 5 analyst ratings, the average rating for IBRX stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 156.00% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
ImmunityBio: Making Its Next Strikes After Bladder Cancer ApprovalImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist, but...
